To further assess the therapeutic effects of the CD19 CAR-UiNK cells on tumor cells in vivo, we established the B-ALL xenograft animal models by transplanting the luciferase-expressing Nalm-6 cells (Nalm-6-luci+) into the NCG immune-deficient mice. This evidence concerns the gene CD19 and neoplasm.